AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15105190
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid treatment (control group)
Trial: 9255857
Drug: Telephone-administered mood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-administered mood ratings (SIGH-SAD)
Trial: 9255857
Drug: Telephone-administered mood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-administered mood ratings (HIGH-SAD)
Trial: 8101467
Drug: Levocabastine (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocabastine (twice daily)
Trial: 8101467
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate (four times daily)
Trial: 3098484
Drug: Intravenous PGE1
RxNorm normalized name: PGE1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous PGE1 infusion
Trial: 27450474
Drug: Intravenous 0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 0.9 mg/kg alteplase plus standard care
Trial: 18971727
Drug: Topical autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical autologous platelet-rich fibrin
Trial: 12651665
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (250 microg) with clonidine (25 microg)
Trial: 12651665
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (250 microg) with clonidine (75 microg)
Trial: 12651665
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (250 microg)
Trial: 10908006
Drug: Matrix treatment
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matrix treatment model for methamphetamine abuse
Trial: 8516522
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of oral omeprazole
Trial: 8516522
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of oral omeprazole
Trial: 3552458
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg penbutolol with 6 mg piretanide
Trial: 23318917
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) using a pulsed 810-nm laser (average power 50 mW, peak power 80 W, 1,500 Hz, 120 s, 6 J, and 3.4 J/cm² per point) applied three times a week for 4 weeks
Trial: 23318917
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (same application as LLLT but without energy output)
Trial: 23591663
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral nutritional supplement drink containing 1.3 mg of vitamin B2, 1.4 mg of vitamin B6, 1.5 μg of B12, 200 μg of folic acid
Trial: 2454376
Drug: Carvedilol (25-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (25-50 mg)
Trial: 29132880
Drug: Rivaroxaban (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (2.5 mg twice a day) plus aspirin (100 mg once a day)
Trial: 27216406
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg betamethasone orally (n=50)
Trial: 27216406
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg betamethasone parenterally (n=25)
Trial: 27216406
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (oral, parenteral, control)
Trial: 22572633
Drug: Allopurinol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (300 mg, p.o.) 24h before administration of radiocontrast agent and hydration (1mg/kg/hN/saline for 12h pre‐ and post‐contrast)
Trial: 18405150
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (oral administration of Sibutramine)
Trial: 16522834
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of oral azithromycin
Trial: 8843511
Drug: Azelastine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine (2 mg; b.i.d.)
Trial: 1398498
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid 5 mg/kg body wt/day
Trial: 1398498
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid 10 mg/kg body wt/day
Trial: 1398498
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid 15 mg/kg body wt/day
Trial: 1398498
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid 20 mg/kg body wt/day
Trial: 27091752
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (600,000 IU vitamin D3 as intramuscular injection)
Trial: 25763201
Drug: CoQ10 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoQ10 (200 mg/d)
Trial: 22507468
Drug: 4% tetracaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% tetracaine gel (Ametop gel)
Trial: 22507468
Drug: 4% liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% liposomal lidocaine gel (LMX4 gel)
Trial: 22507468
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream (2.5% lidocaine and 2.5% prilocaine) applied for 30 min
Trial: 22507468
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream (2.5% lidocaine and 2.5% prilocaine) applied for 60 min
Trial: 20678674
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination treatment with OM 40 mg + AML 10 mg + HCTZ 25 mg
Trial: 20678674
Drug: Dual combinations
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual combinations (OM 40 mg/AML 10 mg, OM 40 mg/HCTZ 25 mg, AML 10 mg + HCTZ 25 mg)
Trial: 20678674
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination treatment
Trial: 15722295
Drug: Ketoprofen patch
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen patch (100 mg) applied once a day for 7 days
Trial: 15722295
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch applied once a day for 7 days
Trial: 10434823
Drug: Cuffed oropharyngeal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cuffed oropharyngeal airway (COPA) as an adjunct to fibreoptic tracheal intubation
Trial: 6260126
Drug: Tinidazole suppositories
RxNorm normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tinidazole suppositories
Trial: 31156170
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with memantine
Trial: 28742713
Drug: EN-EPA (2.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EN-EPA (2.2 g EPA/day)
Trial: 12719078
Drug: Latanoprost 0.005%
RxNorm normalized name: LATANOPROST 0.005% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost 0.005% once daily in the evening
Trial: 12719078
Drug: Bimatoprost 0.03%
RxNorm normalized name: BIMATOPROST 0.03% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimatoprost 0.03% once daily in the evening
Trial: 12719078
Drug: Travoprost 0.004%
RxNorm normalized name: TRAVOPROST 0.004% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Travoprost 0.004% once daily in the evening
Trial: 10852765
Drug: Intravenous GSH
RxNorm normalized name: GSH
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous GSH 70 mg/kg/d
Trial: 10852765
Drug: Intravenous GSH
RxNorm normalized name: GSH
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous GSH 70 mg/kg/d and intravenous NAC 75 mg/kg/d
Trial: 10852765
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard septic shock therapy only)
Trial: 8258959
Drug: n-3 PUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFA (ethyl esters, EPA+DHA = 7.7 g/day)
Trial: 27509605
Drug: Acupuncture at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture at stellate ganglion combined with intravenous administration of alprostadil (10 µg) and sodium chloride solution (100 mL)
Trial: 27509605
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of alprostadil (10 µg) and sodium chloride solution (100 mL)
Trial: 25225285
Drug: Fostamatinib 100
RxNorm normalized name: fostamatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostamatinib 100 mg bid for 24 weeks (Group A)
Trial: 25225285
Drug: Fostamatinib 100
RxNorm normalized name: fostamatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostamatinib 100 mg bid for 4 weeks, then 150 mg qd (Group B)
Trial: 15014210
Drug: Atrial prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial prevention and termination therapies ON (n = 199)
Trial: 15014210
Drug: Atrial prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial prevention and termination therapies OFF (n = 206)
Trial: 15014210
Drug: Atrial prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial prevention and termination therapies ON (subgroup of 192 patients with a history of ATA's)
Trial: 15014210
Drug: Atrial prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial prevention and termination therapies OFF (subgroup of 192 patients with a history of ATA's)
Trial: 815188
Drug: Paracetamol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol plus codeine (P + C) 350 + 20 mg
Trial: 30862526
Drug: Daily undulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily undulating periodization resistance training (DUP)
Trial: 25415247
Drug: Combination 70%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination 70% mineralized: 30% demineralized FDBA
Trial: 23489754
Drug: Minocycline pleurodesis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline pleurodesis (300 mg)
Trial: 21619621
Drug: Full-serve evidence
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-serve evidence service (database access, monthly e-mail alerts, and full-text article availability)
Trial: 18028181
Drug: Antithrombotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic treatment initiation
Trial: 18028181
Drug: Blockers of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blockers of the renin angiotensin system and statins
Trial: 18028181
Drug: Atrial specific
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial specific antiarrhythmic drugs and direct thrombin inhibitors
Trial: 12354317
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of long-term antipsychotic medication
Trial: 9872197
Drug: Albuterol treatment
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol treatment (n=8)
Trial: 9872197
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (n=7)
Trial: 2750674
Drug: High-dose heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose heparin (12,500 U subcutaneously every 12 hours for 10 days)
Trial: 2750674
Drug: Low-dose heparin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose heparin (5,000 U subcutaneously every 12 hours for 10 days)
Trial: 319692
Drug: Caffeine; specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine; specific dosage and duration not mentioned
Trial: 27995939
Drug: Telephone-based management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-based management (weekly advice by telephone for 12 weeks)
Trial: 25819700
Drug: Naltrexone (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (starting dose of 6.25mg, followed by long-acting injectable naltrexone)
Trial: 22000810
Drug: Panitumumab 6
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab 6 mg/kg + FOLFIRI every 2 weeks
Trial: 22000810
Drug: Panitumumab 9
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab 9 mg/kg + irinotecan every 3 weeks
Trial: 31099387
Drug: Losartan +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan + Amlodipine (L/A)
Trial: 31099387
Drug: Losartan +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan + Hydrochlorothiazide (L/H)
Trial: 27869476
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) applied to maxillary incisors with a dose of 2 J/point, starting immediately after archwire insertion and repeated on specific days until the end of the leveling and alignment stage.
Trial: 19135563
Drug: 400 mcg
RxNorm normalized name: Biotin 400 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mcg oral misoprostol
Trial: 19135563
Drug: Both sublingual
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both sublingual and oral misoprostol
Trial: 15300958
Drug: clopidogrel/ASA combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clopidogrel/ASA combination
Trial: 9737514
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment (drug)
Trial: 3361324
Drug: Heparin subcutaneously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin subcutaneously three times daily (doses adjusted based on APTT)
Trial: 3361324
Drug: Heparin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin plus 0.5 mg dihydroergotamine twice daily (fixed dose of 5,000 IU heparin)
Trial: 25262178
Drug: VPA +
RxNorm normalized name: VPA
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VPA + DM60 (60 mg/day)
Trial: 25262178
Drug: VPA +
RxNorm normalized name: VPA
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VPA + DM30 (30 mg/day)
Trial: 16473748
Drug: Topical wheatgrass
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical wheatgrass cream applied twice daily for 6 weeks
Trial: 16473748
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream applied twice daily for 6 weeks
Trial: 12395691
Drug: Antidepressants (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants (specific types not mentioned)
Trial: 2270546
Drug: Indomethacin (3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (3% age oily solution)
Trial: 2270546
Drug: Chlorphenol‐camphor‐menthol‐solution (ChKM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorphenol‐camphor‐menthol‐solution (ChKM) with procain on gauze strip
Trial: 366141
Drug: Continuous treatment
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous treatment of levamisole (150 mg per day)
Trial: 366141
Drug: Intermittent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent treatment of levamisole (3 days per week, 150 mg)
Trial: 366141
Drug: Weekly treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly treatment of levamisole (150 mg one day per week)
Trial: 366141
Drug: Proposed treatment
RxNorm normalized name: Propoven
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proposed treatment scheme of one single weekly dose of 150 mg
Trial: 30784667
Drug: Long-term dual
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term dual antiplatelet therapy (DAPT) in non-high bleeding risk (HBR) patients
Trial: 25052361
Drug: Medication optimization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication optimization at discharge (ACEI or ARB, β-blocker, MRA, diuretics)
Trial: 25052361
Drug: Specific treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific treatment procedures beyond pharmacotherapy
Trial: 25052361
Drug: Medication adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication adherence after 1 year
Trial: 22399699
Drug: Twice-a-week supervised
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-a-week supervised aerobic and resistance training plus exercise counseling
Trial: 19631844
Drug: Various restorative
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various restorative treatments
Trial: 17049818
Drug: Long-acting injectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting injectable risperidone (50 mg/14 days)
Trial: 16409880
Drug: Normal hospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal hospital diet plus oral nutritional supplements (360 ml of 1.5 kcal/ml, 20 g of protein per day) until hospital discharge
Trial: 10826395
Drug: Ca‐antagonist (manidipine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca‐antagonist (manidipine)
Trial: 1813613
Drug: Amantadine (dopamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine (dopamine agonist)
Trial: 15515153
Drug: Individual treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual treatments compared to control
Trial: 12963896
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with a topical retinoid (e.g., adapalene) and an antibiotic
Trial: 12963896
Drug: Topical retinoids
RxNorm normalized name: tocopheryl retinoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical retinoids alone
Trial: 12963896
Drug: Topical or
RxNorm normalized name: aloe vera topical oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical or oral antibiotics
Trial: 10235199
Drug: Domperidone 2
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone 2 x 10‐mg tablets 4 times daily
Trial: 10235199
Drug: Metoclopramide 1
RxNorm normalized name: metoclopramide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 1 x 10‐mg tablet + 1 placebo tablet 4 times daily
Trial: 9094866
Drug: Non-antibiotics
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-antibiotics
Trial: 1811441
Drug: Improved ORS
RxNorm normalized name: Improvest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improved ORS formulation (maltodextrin 20 g, glycine 4 g, glycyl-glycine 4 g)
Trial: 1811441
Drug: Improved ORS
RxNorm normalized name: Improvest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improved ORS formulation
Trial: 31505228
Drug: Remestemcel-L
RxNorm normalized name: remestemcel-L
DrugBank: Remestemcel-L (DB13973)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remestemcel-L
Trial: 30820060
Drug: Sulfamethoxazole-trimethoprim (SMX/TMP)
RxNorm normalized name: sulfamethoxazole / trimethoprim
DrugBank: Sulfamethoxazole (DB01015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfamethoxazole-trimethoprim (SMX/TMP) 200/40 mg
Trial: 30820060
Drug: Sulfamethoxazole-trimethoprim (SMX/TMP)
RxNorm normalized name: sulfamethoxazole / trimethoprim
DrugBank: Sulfamethoxazole (DB01015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfamethoxazole-trimethoprim (SMX/TMP) 400/80 mg
Trial: 21471414
Drug: Volar locking
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volar locking plate fixation with injection of calcium phosphate bone cement (Group 2)
Trial: 19123930
Drug: Exercise program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise program (aerobic and strength exercises) twice a week under supervision of a physiotherapist
Trial: 11599648
Drug: Once-weekly fluoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly fluoxetine (90 mg/week)